A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Acne Vulgaris

Status:
Not yet recruiting

Trial end date:
2022-10-15

Target enrollment:

Participant gender:

Efficacy and Safety of Imsidolimab in Subjects with Acne Vulgaris

Phase 2

AnaptysBio, Inc.